Apr 16, 2016

Network-based Computational Drug Combination Prediction

BioRxiv : the Preprint Server for Biology
Fuhai LiStephen T C Wong

Abstract

Cancers are complex diseases that are regulated by multiple signaling pathways. Patients often acquire resistance to single drug treatment. Use of drug combinations that target multiple parallel pathways is a promising strategy to reduce the drug resistance. Pharmacogenomics big data are being generated to uncover complex signaling mechanisms of cancers and correlate cancer-specific signaling with diverse drug responses. Thus, converting pharmacogenomics big data into knowledge can help the discovery of synergistic drug combination. However, it is challenging and remains an open problem due to the enormous number of combination possibilities and noise of genomics data.

  • References
  • Citations

References

  • We're still populating references for this paper, please check back later.
  • References
  • Citations

Citations

  • This paper may not have been cited yet.

Mentioned in this Paper

Drug Response
Biochemical Pathway
Genomics
Pharmacologic Substance
Pharmacogenomics
Signal Pathways
Pharmacotherapy
Drug Resistance
Malignant Neoplasms
Drug Therapy, Computer-Assisted

About this Paper

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.

Cancer Genomics (Preprints)

Cancer genomics employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest preprints here.